Prenosis

Executive Summary

Prenosis is a Chicago-based biotechnology company pioneering AI-driven diagnostics for acute care, with a focus on sepsis. Its flagship product, the Sepsis ImmunoScore®, is the first FDA-authorized AI diagnostic for sepsis, designed to integrate biomarker and clinical data to aid in diagnosis and predict adverse outcomes. The company aims to enable precision medicine in hospital settings, tailoring treatments to individual patient biology. Founded in 2017, Prenosis has established a strong regulatory foothold and is positioned to expand its platform into other acute conditions. With the growing emphasis on AI in healthcare and the urgent need for early sepsis detection, Prenosis is well-placed to capture significant market share. The company's technology has the potential to improve patient outcomes and reduce healthcare costs, making it an attractive investment opportunity.

Upcoming Catalysts (preview)

• Q4 2026Expansion of ImmunoScore Platform to Additional Indications70% success
• Q3 2026Partnership with Major Hospital Network for Clinical Deployment65% success
• Q2 2026Publication of Real-World Outcomes Data from ImmunoScore Use80% success